PIK3CA and cancer: The most recent results of an ongoing phase I clinical trial (NCT02861300) on CB-839 with Capecitabine (a 5-FU prodrug) for advanced CRC and other solid tumors yielded a better therapeutic outcome for patients with mutated PIK3CA than those with non-mutated cancers.